KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Prepaid Assets (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Prepaid Assets for 18 consecutive years, with $242.1 million as the latest value for Q1 2026.

  • For Q1 2026, Prepaid Assets rose 58.84% year-over-year to $242.1 million; the TTM value through Mar 2026 reached $242.1 million, up 58.84%, while the annual FY2025 figure was $281.9 million, 141.01% up from the prior year.
  • Prepaid Assets hit $242.1 million in Q1 2026 for Alnylam Pharmaceuticals, down from $281.9 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $281.9 million in Q4 2025 and bottomed at $115.1 million in Q1 2022.
  • Average Prepaid Assets over 5 years is $157.8 million, with a median of $145.5 million recorded in 2023.
  • On a YoY basis, Prepaid Assets climbed as much as 141.01% in 2025 and fell as far as 24.53% in 2025.
  • Alnylam Pharmaceuticals' Prepaid Assets stood at $132.9 million in 2022, then decreased by 4.92% to $126.4 million in 2023, then dropped by 7.45% to $117.0 million in 2024, then skyrocketed by 141.01% to $281.9 million in 2025, then fell by 14.11% to $242.1 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $242.1 million, $281.9 million, and $188.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.